Unravelling the Suboptimal Response of TP53 -Mutated Chronic Lymphocytic Leukaemia to Ibrutinib

British Journal of Haematology - United Kingdom
doi 10.1111/bjh.15613
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Lack of Adequate Pneumococcal Vaccination Response in Chronic Lymphocytic Leukaemia Patients Receiving Ibrutinib

British Journal of Haematology
Hematology
2017English

Low-Level TP53 Mutational Load Antecedes Clonal Expansion in Chronic Lymphocytic Leukaemia

British Journal of Haematology
Hematology
2018English

Chronic Lymphocytic Leukaemia

Nature Reviews Disease Primers
Medicine
2017English

Identification of TP53 Aberrations in Chronic Lymphocytic Leukaemia Using Different Molecular Diagnostic Techniques

Pathology
Forensic MedicinePathology
2020English

Comparison of Innate Immunity Changes Following Ibrutinib and Venetoclax Treatment of Relapsed Chronic Lymphocytic Leukaemia

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2017English

Ibrutinib Enhances the Efficacy of ROR1 Bispecific T Cell Engager Mediated Cytotoxicity in Chronic Lymphocytic Leukaemia

British Journal of Haematology
Hematology
2019English

Disseminated Mucormycosis Due to Lichtheimia Corymbifera During Ibrutinib Treatment for Relapsed Chronic Lymphocytic Leukaemia: A Case Report

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

Therapeutic Inhibition of USP7-PTEN Network in Chronic Lymphocytic Leukemia: A Strategy to Overcome TP53 Mutated/Deleted Clones

Oncotarget
Oncology
2017English

Long-Term Ibrutinib Therapy Reverses CD8+ T Cell Exhaustion in B Cell Chronic Lymphocytic Leukaemia

Frontiers in Immunology
AllergyImmunology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy